Turning cold tumors hot: from molecular mechanisms to clinical applications

J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

NAD+ metabolism and its roles in cellular processes during ageing

AJ Covarrubias, R Perrone, A Grozio… - Nature reviews Molecular …, 2021 - nature.com
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme for redox reactions, making it
central to energy metabolism. NAD+ is also an essential cofactor for non-redox NAD+ …

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

C Liu, X Liu, X ** the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
L Xu, C Zou, S Zhang, TSM Chu, Y Zhang… - Journal of hematology & …, 2022 - Springer
The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

NAD+ metabolism, stemness, the immune response, and cancer

LE Navas, A Carnero - Signal transduction and targeted therapy, 2021 - nature.com
NAD+ was discovered during yeast fermentation, and since its discovery, its important roles
in redox metabolism, aging, and longevity, the immune system and DNA repair have been …

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

H Liu, L Tang, Y Li, W **e, L Zhang, H Tang, T **ao… - Molecular Cancer, 2024 - Springer
The incidence of nasopharyngeal carcinoma (NPC) exhibits significant variations across
different ethnic groups and geographical regions, with Southeast Asia and North Africa …

The adenosine pathway in immuno-oncology

B Allard, D Allard, L Buisseret, J Stagg - Nature Reviews Clinical …, 2020 - nature.com
Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …